CANSINOBIO (06185) Secures PIC/S GMP Certification

Stock News03-05

CANSINOBIO (06185) has announced that its production facility for the ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 carrier) (MCV4) and the 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid) (PCV13i) has successfully passed a Good Manufacturing Practice (GMP) compliance inspection conducted by the Malaysian National Pharmaceutical Regulatory Agency (NPRA) under the Pharmaceutical Inspection Co-operation Scheme (PIC/S). The company recently obtained the GMP certificate from the NPRA. PIC/S is an authoritative international organization for drug inspection and certification, comprising regulatory authorities from dozens of countries. It conducts inspections and certifications based on unified GMP standards for both human and veterinary pharmaceuticals. GMP compliance is a prerequisite for drug registration and market approval. On a voluntary basis, PIC/S member states and participating agencies mutually recognize GMP compliance certifications. Securing the PIC/S GMP certification demonstrates that the company's production and quality management systems meet PIC/S GMP standards, which will facilitate the drug registration and market launch processes for MCV4 and PCV13i in Malaysia and other PIC/S member countries.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1104649698?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-05 17:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1104649698","market":"fut","top_or_hot":-1,"title":"CANSINOBIO (06185) Secures PIC/S GMP Certification","media":"Stock News","content":"<p>CANSINOBIO (06185) has announced that its production facility for the ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 carrier) (MCV4) and the 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid) (PCV13i) has successfully passed a Good Manufacturing Practice (GMP) compliance inspection conducted by the Malaysian National Pharmaceutical Regulatory Agency (NPRA) under the Pharmaceutical Inspection Co-operation Scheme (PIC/S). The company recently obtained the GMP certificate from the NPRA. PIC/S is an authoritative international organization for drug inspection and certification, comprising regulatory authorities from dozens of countries. It conducts inspections and certifications based on unified GMP standards for both human and veterinary pharmaceuticals. GMP compliance is a prerequisite for drug registration and market approval. On a voluntary basis, PIC/S member states and participating agencies mutually recognize GMP compliance certifications. Securing the PIC/S GMP certification demonstrates that the company's production and quality management systems meet PIC/S GMP standards, which will facilitate the drug registration and market launch processes for MCV4 and PCV13i in Malaysia and other PIC/S member countries.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CANSINOBIO (06185) Secures PIC/S GMP Certification</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCANSINOBIO (06185) Secures PIC/S GMP Certification\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-05 17:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CANSINOBIO (06185) has announced that its production facility for the ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 carrier) (MCV4) and the 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid) (PCV13i) has successfully passed a Good Manufacturing Practice (GMP) compliance inspection conducted by the Malaysian National Pharmaceutical Regulatory Agency (NPRA) under the Pharmaceutical Inspection Co-operation Scheme (PIC/S). The company recently obtained the GMP certificate from the NPRA. PIC/S is an authoritative international organization for drug inspection and certification, comprising regulatory authorities from dozens of countries. It conducts inspections and certifications based on unified GMP standards for both human and veterinary pharmaceuticals. GMP compliance is a prerequisite for drug registration and market approval. On a voluntary basis, PIC/S member states and participating agencies mutually recognize GMP compliance certifications. Securing the PIC/S GMP certification demonstrates that the company's production and quality management systems meet PIC/S GMP standards, which will facilitate the drug registration and market launch processes for MCV4 and PCV13i in Malaysia and other PIC/S member countries.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"","article_id":"1104649698","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1104649698","pubTimestamp":1772702194,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CANSINOBIO (06185) has announced that its production facility for the ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 carrier) (MCV4) and the 13-valent Pneumococcal...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1574":"生物医药B类股","06185":"康希诺生物","BK1515":"抗疫概念","BK1191":"制药","BK1161":"生物科技"},"translate_title":"康希诺生物(06185)获得PIC/S GMP认证","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06185":1},"content_text":"CANSINOBIO (06185) has announced that its production facility for the ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 carrier) (MCV4) and the 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid) (PCV13i) has successfully passed a Good Manufacturing Practice (GMP) compliance inspection conducted by the Malaysian National Pharmaceutical Regulatory Agency (NPRA) under the Pharmaceutical Inspection Co-operation Scheme (PIC/S). The company recently obtained the GMP certificate from the NPRA. PIC/S is an authoritative international organization for drug inspection and certification, comprising regulatory authorities from dozens of countries. It conducts inspections and certifications based on unified GMP standards for both human and veterinary pharmaceuticals. GMP compliance is a prerequisite for drug registration and market approval. On a voluntary basis, PIC/S member states and participating agencies mutually recognize GMP compliance certifications. Securing the PIC/S GMP certification demonstrates that the company's production and quality management systems meet PIC/S GMP standards, which will facilitate the drug registration and market launch processes for MCV4 and PCV13i in Malaysia and other PIC/S member countries.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1104649698","isCrawlerRequest":true}